文献速递肝病

磁共振弹性成像与振动控制瞬时弹性成像对晚期纤维化非酒精性脂肪性肝病患者纤维化分期的成本效果比较

Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
PubMed 文献 · Hepatology · 2023-01-03

本研究从美国视角构建马尔可夫模型,纳入50岁、Fibrosis-4评分≥2.67且疑似晚期纤维化的NAFLD患者,比较MRE与VCTE作为一线影像策略的成本效果。MRE较VCTE多花费8388美元但多获得1.19质量调整生命年,增量成本效果比为7048美元/QALY;MRE+活检和VCTE+MRE+活检两种策略的增量成本效果比分别为8054美元/QALY和8241美元/QALY。敏感性分析显示MRE在敏感度≥0.77时、VCTE在敏感度≥0.82时仍具成本效果。

要点

  • MRE较VCTE多花费8388美元但多获得1.19 QALY,增量成本效果比7048美元/QALY。
  • MRE+活检与VCTE+MRE+活检的增量成本效果比分别为8054与8241美元/QALY。
  • MRE在敏感度≥0.77时、VCTE在敏感度≥0.82时仍具成本效果。

核心结论

  • 对于Fibrosis-4评分≥2.67的NAFLD患者,MRE作为一线分期手段较VCTE更具成本效果,增量成本效果比为7048美元/QALY。
  • MRE在VCTE无法诊断而作为随访检查使用时仍具成本效果。

研究设计与样本

  • 研究从美国视角构建马尔可夫模型,包含决策树和5种健康状态的马尔可夫状态转换模型。
  • 基础病例为50岁、Fibrosis-4评分≥2.67且疑似晚期纤维化的患者。
  • 模型健康状态包括纤维化1-2期、晚期纤维化、代偿性肝硬化、失代偿性肝硬化和死亡。
  • 研究进行了确定性和概率敏感性分析。

主要发现

  • MRE分期纤维化较VCTE多花费8388美元,但多获得1.19质量调整生命年(QALY),增量成本效果比为7048美元/QALY。
  • 5种策略的成本效果分析显示,MRE+活检和VCTE+MRE+活检最具成本效果,增量成本效果比分别为8054美元/QALY和8241美元/QALY。
  • 敏感性分析表明,MRE在敏感度≥0.77时仍具成本效果,VCTE在敏感度≥0.82时具成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: NAFLD is a common cause of liver disease. To determine the optimal testing strategy for NAFLD patients with advanced fibrosis, several factors such as diagnostic accuracy, failure rates, costs of examinations, and potential treatment options need to be considered. The purpose of this study was to determine the cost-effectiveness of combination testing involving vibration-controlled transient elastography (VCTE) versus magnetic resonance elastography (MRE) as a frontline imaging strategy for NAFLD patients with advanced fibrosis. METHODS: A Markov model was developed from the US perspective. The base-case scenario in this model included patients aged 50 years with a Fibrosis-4 score of ≥2.67 and suspected advanced fibrosis. The model included a decision tree and a Markov state-transition model including 5 health states: fibrosis stage 1-2, advanced fibrosis, compensated cirrhosis, decompensated cirrhosis, and death. Both deterministic and probabilistic sensitivity analyses were performed. RESULTS: Staging fibrosis with MRE cost $8388 more than VCTE but led to an additional 1.19 Quality-adjusted life years (QALYs) with the incremental cost-effectiveness ratio of $7048/QALY. The cost-effectiveness analysis of the 5 strategies revealed that MRE+biopsy and VCTE+MRE+biopsy were the most cost-effective with the incremental cost-effectiveness ratios of $8054/QALY and $8241/QALY, respectively. Furthermore, sensitivity analyses indicated that MRE remained cost-effective with a sensitivity of ≥0.77, whereas VCTE became cost-effective with a sensitivity of ≥0.82. CONCLUSIONS: MRE was not only cost-effective than VCTE as the frontline modality for staging NAFLD patients with Fibrosis-4 ≥2.67 with incremental cost-effectiveness ratio of $7048/QALY but also remained cost-effective when used as a follow-up in instances of VCTE failure to diagnose.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sangha K, Chang ST, Cheung R, et al. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis. Hepatology. 2023. PMID: 37018145. doi:10.1097/HEP.0000000000000262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。